Hawthorn Pharmaceuticals cuts global deal with CoPlex
by MBJ Staff
Published: September 13,2011
MADISON — Hawthorn Pharmaceuticals Inc. has struck an exclusive global licensing deal with CoPlex Therapeutics on hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer’s and other neurodegenerative diseases.
Under the terms of the agreement, Hawthorn will receive an exclusive worldwide license to develop and commercialize hawAD14 and will be responsible for funding all future development.
“In terms of the discovery’s uniqueness, it’s one of only few programs in the world demonstrating multiple protective effects against the predominant pathophysiologic pathways of Alzheimer’s disease,” said Rob Lewis, chief scientific officer at Hawthorn Pharmaceuticals.
“We are in the process of conducting the necessary preclinical studies in order to file an IND with the FDA,” said Max Draughn, Hawthorn Pharmaceuticals’ CEO.
To sign up for Mississippi Business Daily Updates, click here.
Top Posts & Pages
- WILLOUGHBY: Bernie Reed cites hard work as key to success of Reed’s Metals
- Half century of memories — Christmas on Deer Creek to celebrate 50th anniversary
- Analyst: KiOR Columbus plant may end up sold as scrap
- (UPDATE) Gov. Bryant: $1.2 billion aluminum plant is a very exciting proposition for the state of Mississippi
- Ex-MDEQ leader Fisher joins Butler Snow
- Former MDEQ Executive Director Trudy Fisher joins Butler Snow
- Federal appeals court: State's abortion law is unconstitutional
- Can Metrocenter rise from the ashes? Again
- Gulf oil rig explosion kills one worker, injures three
- Prescott leads field for Conerly Trophy as state's best football player